Together, we can transform the future of cancer care.
Tracking early stage breast cancer with ultrasensitive ctDNA
Information for patients with breast cancer
Monitoring therapy response with ultrasensitive ctDNA across cancer types
Ultrasensitive ctDNA detection in early-stage lung cancer
Personalis is transforming the development of next-generation therapies.
At Personalis, our mission is to transform the active management of cancer through breakthrough personalized testing. Our advanced genomic tests detect ultra-low traces of minimal residual disease (MRD) and recurrence, uncover deeper insights for therapy selection, and power the design of individualized neoantigen therapies.
Personalis was founded in 2011 by a team of internationally-renowned next-generation sequencing (NGS) thought-leaders from Stanford University. We’re committed to building a world where personalized testing provides greater confidence and exceptional outcomes for cancer patients.
Our headquarters – housing our CLIA-certified, CAP-accredited laboratory – recently relocated to a state-of-the-art facility in Fremont, CA.
